Immunotherapy with antigen specific lymphocytes selected in vitro after nonmyeloablative lymphocyte suppressive chemotherapy

摘要

Use of (a) a nonmyeloablative chemotherapeutic agent for lymphocyte suppressants, and (b1) autologous T lymphocytes, which have been previously isolated, selected for the high avidity for a cancer antigen, whose regression is to be promoted, and expanded in vitro only once, and (b2) a T lymphocyte growth factor that promotes the growth and activation of autologous T lymphocytes, in the preparation of a medicament to promote the regression of a cancer in a mammal, in which (b1) and (b2) are administered subsequently to the administration of (a), and in which (b2) is administered concomitantly with (b1) or subsequently to (b1), by the same or a different route.